Shopping Cart
- Remove All
- Your shopping cart is currently empty
GSK-J1 lithium salt is an effective inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A, with an IC 50 of 60 nM for KDM6B.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks | |
100 mg | Inquiry | 10-14 weeks |
Description | GSK-J1 lithium salt is an effective inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A, with an IC 50 of 60 nM for KDM6B. |
Targets&IC50 | JMJD3 (KDM6B):60 nM |
In vitro | GSK-J1 selectively targets and binds to the endogenous JMJD3 within the KDM6 subfamily of H3K27 demethylases, effectively inhibiting TNF-α production in human primary macrophages through an H3K27-dependent process [1]. Additionally, it demonstrates an 8.5-fold higher inhibitory potency against KDM5C's demethylase activity compared to KDM5B when assessed at 1 mM α-ketoglutarate, with respective IC50 values of 11 μM and 94 μM [3]. |
Molecular Weight | 395.38 |
Formula | C22H22LiN5O2 |
Cas No. | 2309668-29-7 |
Relative Density. | no data available |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.